|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Cretostimogene Grenadenorepvec: A Novel Oncolytic Immunotherapy for BCG-Unresponsive NMIBC |
Roger Li, MD
Zach Klaassen interviews Roger Li about the CORE-001 trial for BCG-unresponsive non-muscle invasive bladder cancer. Dr. Li highlights the significant need for bladder-sparing therapies for patients who are too frail or unwilling to undergo radical cystectomy. |
|
|
|
|
|
|
|
|
|
|
| Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial |
|
Neal Shore, MD, FACS
|
| Sam Chang interviews Neal Shore about the KEYNOTE-992 trial comparing immunotherapy combined with chemoradiation to standard trimodality therapy for muscle-invasive bladder cancer. Dr. Shore explains that the trial evaluates Pembrolizumab with chemoradiation versus placebo with chemoradiation in patients suitable for bladder-sparing approaches.
|
|
|
|
|
|
|
|
|
|
|
|
| NIAGARA Trial: Chemo Plus Durvalumab Improves Survival in Muscle-Invasive Bladder Cancer |
| Thomas Powles, MBBS, MRCP, MD |
| Shilpa Gupta interviews Thomas Powles about the NIAGARA study, which examines perioperative chemoimmunotherapy in muscle-invasive bladder cancer. Dr. Powles discusses the trial's design, combining durvalumab with chemotherapy before and after cystectomy, highlighting its significant improvements in event-free and overall survival. |
|
|
|
|
|
|
|
|
|
|
|
| Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy |
| Ananya Choudhury, PhD, MA, MRCP, FRCR |
| Ananya Choudhury highlights the need for more personalized radiotherapy (RT) in bladder cancer, particularly due to the underutilization of radical therapies in certain patient populations. She emphasized the advances in adaptive radiotherapy, such as daily image-guided adjustments, and the potential for biomarkers to tailor treatment further. The RAIDER study demonstrated the efficacy of bladder-preserving RT, and Dr. Choudhury discussed the future of RT in improving patient selection and treatment intensification, especially for those currently underserved. |
|
|
|
|
|
| Nivolumab plus Chemoradiotherapy in Patients with Non-Metastatic Muscle-Invasive Bladder Cancer, Not Undergoing Cystectomy: A Phase II, Randomized Study by the Hellenic GU Cancer Group |
| Andromachi Kougioumtzopoulou MD |
| Andromachi Kougioumtzopoulou presented a phase II study investigating the addition of nivolumab to chemoradiotherapy (TMT) in patients with non-metastatic muscle-invasive bladder cancer not undergoing cystectomy. The study demonstrated a significant improvement in bladder cancer failure-free survival and 2-year overall survival for the nivolumab plus TMT arm compared to chemoradiotherapy alone. |
|
|
|
|
|
|
|
|
|
|
| Enfortumab Vedotin plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology: A Phase II Study |
| Bassel Nazha, MD, MPH |
| Bassel Nazha presents an ongoing phase II study evaluating the combination of enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic bladder cancer of variant histology. This trial targets non-urothelial and variant histology bladder cancers, which are underrepresented in major trials. The study's primary endpoint is the objective response rate, with secondary endpoints including progression-free survival, overall survival, and safety. |
|
|
|
|
|
| Perioperative Sacituzumab Govitecan Alone or in Combination with Pembrolizumab for Patients with Muscle-Invasive Urothelial Bladder Cancer: SURE-01/02 Interim Results |
| Antonio Cigliola, MD |
| Antonio Cigliola presents the interim results from the SURE-01/02 trial, which evaluates perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab in patients with muscle-invasive urothelial bladder cancer (MIBC). This trial is critical for cisplatin-ineligible or cisplatin-refusing patients, a population with poor prognosis. |
|
|
|
|
|
Evaluating Antibody-Drug Conjugates Combination with Radiation Therapy in Bladder Cancer - Expert Commentary
|
| Bishoy M. Faltas, MD |
| This expert commentary discusses a study evaluating the combination of antibody-drug conjugates (ADCs) enfortumab vedotin (EV) and sacituzumab govitecan (SG) with radiation therapy in bladder cancer. Results showed variability in target expression but demonstrated additive effects of radiation and ADCs in inducing DNA damage and apoptosis in cancer cells, with combination treatment reducing tumor size in a mouse model. |
|
|
|
|
|
| First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab Nab-Paclitaxel Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer |
| Chiara Mercinelli, MD |
| The NURE-Combo trial presented at EAU 2024 evaluated the combination of neoadjuvant nivolumab and nab-paclitaxel followed by adjuvant nivolumab in patients with muscle-invasive bladder cancer. Results showed a 39% pathologic complete response rate, with 73.3% of patients achieving a ≤ypT1N0 response. These findings suggest that this combination could offer a viable perioperative strategy, especially for cisplatin-ineligible patients, and support the potential for organ-sparing approaches. |
|
|
|
|
|
